Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial.

Autor: George DJ; Duke Cancer Institute, Duke University Medical Center, Durham, North Carolina, USA daniel.george@duke.edu., Hessel C; Exelixis, Inc., Alameda, California, USA., Halabi S; Alliance Statistics and Data Center, and Department of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina, USA., Michaelson MD; Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA., Hahn O; Alliance Protocol Operations Office, Chicago, Illinois, USA., Walsh M; Dana-Farber/Partners CancerCare, Boston, Massachusetts, USA., Picus J; Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri, USA., Small EJ; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, USA., Dakhil S; University of Kansas - Wichita, Wichita, Kansas, USA., Feldman DR; Memorial Sloan Kettering Cancer Center, New York, New York, USA., Mangeshkar M; Exelixis, Inc., Alameda, California, USA., Scheffold C; Exelixis, Inc., Alameda, California, USA., Morris MJ; Memorial Sloan Kettering Cancer Center, New York, New York, USA., Choueiri TK; Dana-Farber/Partners CancerCare, Boston, Massachusetts, USA.
Jazyk: angličtina
Zdroj: The oncologist [Oncologist] 2019 Nov; Vol. 24 (11), pp. 1497-1501. Date of Electronic Publication: 2019 Aug 09.
DOI: 10.1634/theoncologist.2019-0316
Abstrakt: Cabozantinib treatment prolonged progression-free survival (PFS) and improved objective response rate (ORR) compared with sunitinib in patients with advanced renal cell carcinoma (RCC) of intermediate or poor risk by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) criteria in the phase II CABOSUN trial (NCT01835158). In the trial, 157 patients were randomized 1:1 to receive cabozantinib or sunitinib, stratified by IMDC risk group and presence of bone metastases. Here, PFS and ORR, both determined by independent radiology committee (IRC), were analyzed by subgroups of baseline characteristics. Cabozantinib treatment was generally associated with improved PFS and ORR versus sunitinib across subgroups, including in groups defined by IMDC risk group, bone metastases, age, and tumor burden. Clinical trial identification number NCT01835158.
Competing Interests: Disclosures of potential conflicts of interest may be found at the end of this article.
(© 2019 The Authors. The Oncologist published by Wiley Periodicals, Inc. on behalf of AlphaMed Press.)
Databáze: MEDLINE
Externí odkaz: